Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: psoriasis

3 AC&R Study Summaries: Avoidable RA Hospitalizations, Psoriasis to Psoriatic Arthritis Transition, & Neighborhood Conditions in Childhood Lupus

  |  

New studies reveal predictors for avoidable RA hospitalizations, PsA transition in psoriasis & the impact of neighborhood on childhood lupus.

What Clinical Factors Affect Length of Transition to Psoriatic Arthritis in Patients with Psoriasis?

Shashank Cheemalavagu, MD, Yuxuan Jin, MS, & M. Elaine Husni, MD, MPH  |  

Objective We aimed to identify clinical and demographic features associated with the interval between the appearance of psoriasis and the onset of psoriatic arthritis (PsA). Methods We identified patients with psoriasis and PsA diagnoses from our tertiary care psoriatic disease biorepository: a longitudinal, real-world database including clinical information and patient-reported outcomes. We used a multivariable,…

Many Medications: Understanding the Biologic Management of Psoriasis

  |  

ORLANDO, FLORIDA — Given the intersection between rheumatology and dermatology for many patients with autoimmune diseases, it’s helpful to hear from specialists in both fields regarding disease management strategies.

Risk of IBD in Patients with Psoriasis, PsA & Ankylosing Spondylitis Starting IL-17 Inhibitors

  |  

In February A&R, Penso et al. reported on the results of their study, which explored whether patients with psoriasis, PsA and AS have a higher risk of developing IBD when treated with an IL-17 inhibitor compared with apremilast, a phosphodiesterase 4 (PDE4) inhibitor, or etanercept, a TNF inhibitor.